title: Advances in care of children with hemophilia.
abstract: Care for children with severe hemophilia has moved from pediatric hospital wards and rehabilitation services to the home, school, and community. Advances in hemophilia are due largely to the development of specialized hemophilia treatment centers, which created a system of comprehensive care and focused healthcare efforts on prevention and education. Parallel advances in coagulation resulted in identification of clotting factors VIII and IX, elucidation of the protein molecular and biochemical structures and functions, sequencing of their respective genes and transfer of the human genes for production of proteins by recombinant technology, and development of gene therapy. The tragedy of the human immunodeficiency virus and hepatitis C raised awareness in patients as well as healthcare providers of the vulnerability of blood products to viral contamination and spurred progress in science leading to viral inactivation of purified proteins. Concomitantly, physicians treating bleeding episodes in the clinic investigated pharmacokinetics and pharmacoeconomics of various strategies of clotting factor replacement. The observation that trough factor levels as low as 1 to 2% were adequate to prevent most bleeding episodes led to current prophylactic regimens that allow boys to participate fully in school and community activities while factor concentrate is infused at home on a regular schedule. Currently, children with hemophilia look forward to a normal life expectancy and excellent health-related quality of life. Physician and community partnerships through research and advocacy societies have accelerated clinical advancements as well as extension of treatment to developing countries. The future of hemophilia promises a cure with gene therapy. Given the past accomplishments in hemophilia, a long-term solution to replacement of the genetically deficient protein lies on the horizon.
authors.affiliation: Mountain States Regional Hemophilia and Thrombosis Center, University of Colorado Health Sciences Center and The Children's Hospital, Denver, Colorado, USA. marilyn.manco-johnson@uchsc.edu
authors.forename: Marilyn J
authors.initials: MJ
authors.lastname: Manco-Johnson
authors.forename: Brenda
authors.initials: B
authors.lastname: Riske
authors.forename: Carol K
authors.initials: CK
authors.lastname: Kasper
mesh_terms: D001777:Blood Coagulation; D016913:Blood Component Transfusion; D002648:Child; D003906:Developing Countries; D005169:Factor VIII / Q000627:therapeutic use; D015316:Genetic Therapy; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans; D007108:Immune Tolerance; D007592:Joint Diseases / Q000209:etiology / Q000517:prevention & control; D010290:Parents / Q000193:education; D012648:Self Care
chemical_list: D005169:Factor VIII